Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
Navani V, Meyers DE, Ruan Y, Boyne DJ, O'Sullivan DE, Dolter S, Grosjean HA, Stukalin I, Heng DYC, Morris DG, Brenner DR, Sangha R, Cheung WY, Pabani A. Navani V, et al. Among authors: dolter s. Clin Lung Cancer. 2023 May;24(3):e152-e159. doi: 10.1016/j.cllc.2022.12.014. Epub 2023 Jan 20. Clin Lung Cancer. 2023. PMID: 36774234 Free article.
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, Goutam S, Navani V, Heng DYC, Cheung WY, Morris DG, Pabani A. Meyers DE, et al. Among authors: dolter s. JTO Clin Res Rep. 2023 Feb 24;4(4):100482. doi: 10.1016/j.jtocrr.2023.100482. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37090101 Free PMC article.
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL, Stukalin I, Meyers DE, Dudani S, Grosjean HAI, Dolter S, Ewanchuk BW, Goutam S, Sander M, Wells C, Pabani A, Cheng T, Monzon J, Morris D, Basappa NS, Pal SK, Wood LA, Donskov F, Choueiri TK, Heng DYC. Gan CL, et al. Among authors: dolter s. Eur J Cancer. 2021 Jul;151:115-125. doi: 10.1016/j.ejca.2021.04.004. Epub 2021 May 8. Eur J Cancer. 2021. PMID: 33975059 Free article.
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.
Grosjean HAI, Dolter S, Meyers DE, Ding PQ, Stukalin I, Goutam S, Kong S, Chu Q, Heng DYC, Bebb DG, Morris DG, Cheung WY, Pabani A. Grosjean HAI, et al. Among authors: dolter s. Curr Oncol. 2021 Oct 18;28(5):4213-4222. doi: 10.3390/curroncol28050357. Curr Oncol. 2021. PMID: 34677275 Free PMC article.